The prevalence, patterns and predictors of diabetic peripheral neuropathy in a developing country by Prasad Katulanda et al.
Katulanda et al. Diabetology & Metabolic Syndrome 2012, 4:21
METABOLIC SYNDROME
DIABETOLOGY & http://www.dmsjournal.com/content/4/1/21RESEARCH Open AccessThe prevalence, patterns and predictors of
diabetic peripheral neuropathy in a
developing country
Prasad Katulanda1,2*, Priyanga Ranasinghe3, Ranil Jayawardena1,4, Godwin R Constantine1, M H Rezvi Sheriff1 and
David R Matthews2Abstract
Prevalence of diabetes mellitus (DM) has reached epidemic proportions in Sri Lanka. Presently there are studies on
the community prevalence of distal peripheral neuropathy (DPN) in Sri Lanka. We describe prevalence, patterns and
predictors of DPN in patients with DM in Sri Lanka. Data were collected as part of a national study on DM. In new
cases DPN was assessed using the Diabetic-Neuropathy-Symptom (DNS) score, while in those with established
diabetes both DNS and Toronto-Clinical-Scoring-System (TCSS) were used. A binary logistic-regression analysis was
performed with ‘presence of DPN’ as the dichomatous dependent variable and other independent co-variants. The
study included 528 diabetic patients (191-new cases), with a mean age of 55.0 ± 12.4 years and 37.3% were males,
while 18% were from urban areas. Prevalence of DPN according to DNS score among all patients, patients with
already established diabetes and newly diagnosed patients were 48.1%, 59.1% and 28.8% respectively. Prevalence of
DPN in those with established DM as assessed by TCSS was 24% and the majority had mild DPN (16.6%). The
remainder of the abstract is based on subjects with established DM. The prevalence of DPN in males and female
was 20.0% and 26.4% respectively. The mean age of those with and without DPN was 62.1 ± 10.8 and
55.1 ± 10.8 years respectively (p< 0.001). The majority of those with DPN were from rural-areas (75.3%) and earned a
monthly income< Sri Lankan Rupees 12,000 (87.6%). In the binary logistic-regression presence of foot ulcers
(OR:10.4; 95%CI 1.8–16.7), female gender (OR:6.7; 95%CI 2.0–9.8) and smoking (OR:5.9; 95%CI 1.4–9.7) were the
strongest predictors followed by insulin treatment (OR:4.3; 95%CI 1.3–6.9), diabetic retinopathy (OR:2.7; 95%CI 1.3–
5.4), treatment with sulphonylureas (OR:1.8; 95%CI 1.1–3.2), increasing height (OR:1.8; 95%CI 1.2–2.4), rural residence
(OR:1.8; 95%CI 1.1–2.5), higher levels of triglycerides (OR:1.6; 95%CI 1.2–2.0) and longer duration of DM (OR:1.2; 95%
CI 1.1–1.3). There is a high prevalence of DPN among Sri Lankan adults with diabetes. The study defines the impact
of previously known risk factors for development of DPN and identifies several new potential risk factors in an
ethnically different large subpopulation with DM.
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Diabetes mellitus (DM) has reached epidemic propor-
tions worldwide. Historically, diabetes was considered a
disease confined to developed countries and affluent
people. However, recent estimates suggest that the preve-
lence of diabetes is rising globally, particularly in devel-
oping countries [1]. Diabetes mellitus has become an
important health concern in the South Asian region with
an estimated increase in the prevalence of diabetes of
over 151% between 2000 and 2030 [1]. Neuropathy is
considered the most common micro-vascular complica-
tions of both types 1 and 2 diabetes mellitus [2,3].
Neuropathic disorders in diabetes can impair functioning
of the central, peripheral and/or autonomic nervous sys-
tems [4]. Distal peripheral neuropathy (DPN), also
known as diabetic polyneuropathy affects the peripheral
nervous system and is by far the most common type of
neuropathy seen in DM [5]. The resultant loss of func-
tion in peripheral nerves causes loss of protective sen-
sations and impairs patient’s ability to perceive
incipient or even apparent ulcerations in the feet. DPN
is considered a main risk factor for amputation, and
hence a significant cause of morbidity in DM [6].
Although a common and important complication of
diabetes, neuropathy has not been studied as often
or as extensively as macro-vascular complications or
retinopathy and nephropathy [7]. In addition, the
reported prevalence estimates vary widely between
countries, in part due to the difference in sampling
methods and lack of consensus on diagnostic criteria
[8]. Hence, for comparative purposes it is important
to use studies that utilize similar diagnostic criteria.
However, the observed variations in prevalence could
partly result from ethnic differences in predisposition
and differential exposure to risk factors.
Increasing age, longer duration of diabetes and poor
glycaemic control are well recognized risk factors for
DPN, while cigarette smoking, retinopathy, hypertension,
obesity, hyperlipidaemia and microalbuminuria have also
been implicated as potential risk markers [9]. Most
prevalence and risk factor studies are from western
developed countries, while there is a relative scarcity of
data from developing countries, particularly from the
South-Asian region [10]. However, an estimated 80% of
the global population with diabetes lives in developing
countries [1]. The South-Asian population in particular
is known to have an increased predisposition for the dis-
ease [11]. In addition, several studies have demonstrated
that the risk of diabetes related amputations and the
prevalence of diabetic foot ulcers in UK is significantly
lower in diabetic patients of Asian origin when compared
to that of diabetic patients of European origin [12,13].
This reduced risk in Asians was found to be related to
the lower incidence of peripheral arterial disease andDPN. Ethnic differences and differential environmental
exposure to risk factors in the different populations are
other proposed mechanisms. Hence studies aimed at de-
fining the extent of DPN and the associated risk factors
in this vast subpopulation of diabetic patients would help
to improve preventive strategies.
Sri Lanka is a developing country in the South Asian
region with a population of 20.9 million [14]. The preva-
lence of DM has reached epidemic proportions in Sri
Lanka with recent studies demonstrating that one in
every five adults aged> 20 years has either diabetes or
pre-diabetes [15]. To our knowledge, there are no pub-
lished data regarding the community prevalence of DPN
in Sri Lanka. The present study aims to describe the
community prevalence, patterns and predictors of distal
peripheral neuropathy among patients with diabetes
mellitus in Sri Lanka with a view of identifying differen-
tial risk factors, which may lead to improved preventive
measures and care for diabetic patients in the South Asia
region.
Materials and methods
Study population and sampling
Data were collected as part of a wider cross-sectional
national study on diabetes conducted in seven of the
nine provinces in Sri Lanka between August 2005 and
September 2006 (Sri Lanka Diabetes and Cardiovascular
Study – SLDCS). In the SLDCS, the research team ran-
domly selected 100 clusters (of 50 adults each) to repre-
sent seven out of nine provinces in the country. The
sample sizes for each province were determined using a
probability-proportional to-size (PPS) technique based
on total population of each province. Each cluster was
selected by a computer-generated random number list
from the ‘Village Office Units’ in each province. Voter
registration lists were used to randomly select the first
household in each cluster and a uniform criterion was
used to select the remaining 49 households. Detailed
sampling has been previously reported [15]. Relevant
data of 5000 non-institutionalized adults are presented
here. The ethical approval for the study was obtained
from the Ethical Review Committee, Faculty of Medi-
cine, University of Colombo, Sri Lanka.
Definitions
Subjects were considered to have ‘diagnosed diabetes’ if
they had been previously diagnosed at a government
hospital or by a registered medical practitioner. New
cases (‘undiagnosed diabetes’) were diagnosed according
to the American Diabetes Association [16] and World
Health Organization (WHO) criteria [17]. Obesity was
defined as a body mass index (BMI) ≥ 27.5 kg/m2, based
on WHO criteria for Asians [18]. Presence/absence of
diabetic retinopathy was determined by standardized
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ent ophthalmologists, and classified as background, pre-
proliferative, proliferative, advanced retinopathy and
maculopathy. Nephropathy was defined as the presence
of micro-albuminuria (30 – 299 mg/day) or macro-
albuminuria (≥ 300 mg/day), or by review of medical
records [19].
Data collection
In new cases, DPN was assessed using the validated Dia-
betic Neuropathy Symptom (DNS) Score, while in ‘diag-
nosed diabetes’ subjects both DNS and the validated
Toronto Clinical Scoring System (TCSS) was used [20].
The DNS score derives from the assessment of 4 symp-
toms, the presence of each symptom is scored 1. DPN is
considered to be present if score is between 1 and 4
[21]. The TCSS produces a score derived from the clin-
ical assessment of 6 symptoms, 5 sensory tests, and
lower limb reflexes, giving a maximal score of 19. The
degree of neuropathy was based on the TCSS score used
in a previous study (no neuropathy: ≤5, mild neuropathy:
6–8, moderate neuropathy: 9–11 and severe neuropathy:
≥12) [20]. Sensation was tested on the dorsum and tip of
the first toe. Light touch, pain sense, vibration sense and
temperature sense were tested using a 10-gram Semmes-
Weinsten monofilament, a pinprick, a 128 Hz tuning
fork and a cylinder with different temperatures respect-
ively. Tendon reflex was tested by striking the Quadri-
ceps and Achilles tendons with a reflex hammer.
Height was measured using Harpenden stadiometers
(Chasmors Ltd, London, UK) to the nearest 0.1 cm, as
the maximum distance to the uppermost position on
the head from heels, with the individual standing bare-
foot and in full inspiration. Body weight was measured
using a SALTER 920 digital weighing scale (SALTER
Ltd, Tonbridge, UK) to the nearest 0.1 kg after an
overnight fast and with indoor light clothing. BMI was
calculated as weight in kilograms divided by height
squared in meters (kg.m-2). Waist circumference was
measured midway between the iliac crest and the lower
rib margin at the end of normal expiration and hip cir-
cumference was measured at the widest level over the
greater trochanters using a plastic flexible tape to the
nearest 0.1 cm. Seated blood pressure was measured
after at least a 10-min rest with Omron IA2 digital
blood pressure monitors (Omron Healthcare, Singa-
pore). Fasting venous blood samples were obtained for
glucose andlipid estimation from all participants, details
of analysis have been previously described [15]. Data
on physical activity were collected using the short ver-
sion of the International Physical Activity Question-
naire. Subjects in the ‘moderate’/‘high’ physical activity
categories were considered as being physical active
[22].Statistical analyses
Data were analysed using SPSS v14 (SPSS Inc., Chicago,
IL, USA) statistical software package. The significance of
the differences between proportions and means was
tested using z-test and Student’s t-test or ANOVA re-
spectively. A binary logistic regression analysis was per-
formed in all patients with ‘presence of DPN’ as the
dependent variable (0 =DPN absent; 1 =DPN present)
and gender (0 =male; 1 = female), sector of residence
(0 =Urban, 1 = Rural), household income (0 => LKR
25,000; 1 = LKR 12,000 – 25,000; 2 =< LKR 12,000),
height, triglyceride levels, duration of diabetes, current
smoking (0 = no, 1 = yes), current alcohol consumption
(0 = no, 1 = yes), retinopathy (0 = absent, 1 = present),
nephropathy (0 = absent, 1 = present), Foot ulcers (0 = ab-
sent, 1 = present), Obesity (0 = BMI< 27.5, 1 =BMI≥
27.5), hypertension (0 = absent, 1 = present), physical ac-
tivity (0 = active, 1 = inactive), drug treatment (0 =met-
formin, 1 = sulfonylurea) and treatment with insulin
(0 = not treated, 1 = treated) as the independent variables.
The variables were selected by a forward selection pro-
cedure based on increment of R2. In all statistical ana-
lyses p< 0.05 was considered significant.
Results
Out of the 5000 invited subjects, 4477 participated in
the study (response rate 89.5%). This report is based on
528 subjects (11.9%) with DM after excluding 6 subjects
with incomplete data (191 new cases [36.2%]). Details of
subject recruitment are presented in Figure 1. The mean
age was 55.0 ± 12.4 years, 37.3% were males and only 3
patients were suffering from Type 1 DM. Majority of the
subjects were treated with metformin (61.3%) and sul-
phonylureas (48.4%). Glitazones were used in 4.2%, while
insulin was administered in 3.9% of the patients. The
prevalence of DPN according to the DNS score among
all patients, patients with already established diabetes
and newly diagnosed patients was 48.1% (n = 254), 59.1%
(n = 199) and 28.8% (n = 55) respectively. The most com-
mon symptom among newly diagnosed subjects were
burning, aching pain or tenderness of feet (n = 30,
15.7%), followed by numbness of feet (n = 24, 12.6%),
prickling sensation of feet (n = 22, 11.5%) and unsteadi-
ness in walking (n = 20, 10.5%).
The remainder of this article is based exclusively on
subjects with established DM only (n = 337), in whom
both symptoms and signs of neuropathy were evaluated.
DPN is considered to be present in all subjects with
TCSS> 5. In subjects with established DM the preva-
lence of DPN according to the TCSS score was 24.0%
and a majority was suffering from mild neuropathy
(n = 56, 16.6%) (Table 1). In patients with established
diabetes the most common symptom was the presence
of numbness of feet (n = 125, 37.1%) followed by
Total number of subjects 
invited = 5,000
(50 adults from 100 clusters)
Response rate – 89.5%
(n = 4,477 )
Prevalence of DM – 11.9%
(n = 534)
Exclusion of those with 
incomplete data
(n = 6)






Figure 1 Schematic representation of subject recruitment
Table 1 Socio-demographic characteristics and
prevalence of Distal Peripheral Neuropathy among








Mean age (±SD) 44.9 ± 15.0 51.4 ± 13.5 56.8 ± 11.2
Gender (%)Male 1572 (39.8%) 72 (37.7%) 125 (37.1%)
Female 2377 (60.2%) 119 (62.3%) 212 (62.9%)
































* NA – Not applicable.
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32.3%), prickling sensation of feet (n = 100, 29.7%) and
unsteadiness (n = 86, 25.5%). On clinical examination of
subject with established DM, impaired big-toe pin prick
sensation was the commonest sensory deficit (n = 134,
39.7%), followed by impaired light touch (n = 129,
38.3%), vibration (n = 88, 26.1%), joint position (n = 56,
16.6%) and temperature sensations (n = 28, 8.3%). Ankle
and knee reflexes were absent or diminished in 28.2%
(n = 95) and 11.6% (n = 39) of patients respectively. The
prevalence of DPN among all, male and female patients
was 24.0% (n = 81/337), 20.0% (n = 25/125) and 26.4%
(n = 56/212) (males vs. females, p> 0.05). The mean age
(±SD) of patients with or without DPN was
62.1 ± 10.8 years and 55.1 ± 10.8 years respectively (p
< 0.001). Socio demographic characteristics of subjects
with or without DPN are presented in Table 2. A major-
ity of patients with DPN were residing in rural areas
(75.3%) and earned a monthly income of< Sri Lankan
Rupees (LKR) 12,000 (87.6%). The mean duration of DM
among patients with DPN was 7.8 ± 7.1 years, while
among patients without DPN it was 5.8 ± 5.0 years
(p< 0.01). The presence of foot ulcers were significantly
greater in patients with DPN (n = 11, 64.7%) than those
without DPN (n = 6, 35.3%) (p< 0.001).
Subjects with DPN were significantly taller and they had
a lower body weight, BMI, waist circumference, hip circum-
ference and elevated levels of triglycerides (Table 3). How-
ever, the strength of association (Spearmans’ correlation)was low (<±0.2) for all of the above factors. No signifi-
cant difference was observed in the systolic and the dia-
stolic blood pressure, total cholesterol, LDL cholesterol
and HDL cholesterol (Table 3). A binary logistic regres-
sion was used to identify potential risk factors and asso-
ciations of DPN in subjects with DM. Presence of foot
ulcers, female gender and current smoking were the most
significantly and strongly associated factors followed by
treatment with insulin, presence of diabetic retinopathy,
Table 2 Socio-demographic characteristics of diabetic
subjects with or without DPN
DPN present DPN absent
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LKR - Sri Lankan Rupees.
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sector of residence, higher fasting triglyceride levels,
lower household income and longer duration of diabetes
after adjusting for age (Table 4). However the presence of
hypertension, obesity, nephropathy, alcohol consumption
and physical inactivity were not significant predictors of
DPN in patients with DM.
Discussion
DPN is a common complication of DM. This is the first
comprehensive report on DPN among DM patients from
a nationally representative community based sample
from Sri Lanka. The Western, Southern, Sabaragamuwa,
Uva, North-Western, Central and North-Central pro-
vinces were included while the Northern and Eastern
provinces affected by the war had to be excluded. The
prevalence of DPN according to the DNS and the TCSSTable 3 Physical characteristics and biochemical parameters o
Mean (±SD)
DPN present
Height (cm) 155.7 (±9.0)
Weight (kg) 54.6 (±11.5)
Body mass index (kg/m2) 22.8 (±3.6)
Waist circumference (cm) 83.2 (±11.7)
Hip circumference (cm) 90.9 (±8.9)
Waist-hip ratio 0.92 (±0.08)
Systolic blood pressure (mmHg) 140 (±25)
Diastolic blood pressure (mmHg) 78 (±12)
Total cholesterol (mg/dl) 217.4 (±49.3)
LDL cholesterol (mg/dl) 138.8 (±38.5)
HDL cholesterol (mg/dl) 47.4 (±9.5)
Triglycerides (mg/dl) 162.1 (±97.4)scores was 48.1% and 24.0% respectively. The diagnosis
of DPN is complicated and requires the assessment of
multiple features of neuropathy as DPN affects a variety
of nerve fibres. [23]. For full classification the San Anto-
nio Conference on diabetic neuropathy recommends the
assessment of at least one measure from each of the fol-
lowing categories: neuropathic symptoms, clinical exam-
ination, electro-diagnostic tests, quantitative sensory
tests and autonomic function tests [24]. Thus, the TCSS
which incorporates both assessment of symptoms and
signs can be considered more accurate for comparative
studies. Sri Lankan community-based prevalence of
DPN is comparable with that reported from India, Ban-
gladesh and UK using similar diagnostic criteria. How-
ever, the prevalence of DPN in Sri Lanka is significantly
lower than in other regional, developing and developed
countries (Table 5), differences in diagnostic methodolo-
gies could partially account for this difference. Ethnic
differences in predisposition and differential exposure to
risk factors are other probable mechanisms. Most stud-
ies are based on either in-hospital patients or follow-up
patients attending diabetic clinics. Recent reviews have
noted that “knowledge on the epidemiology of DPN is
compromised by the lack of large population-based stud-
ies” [8].
In the present study there was a significant association
between the use of insulin and presence of DPN. Some
have postulated that exogenous insulin therapy in
T2DM might be associated with DPN through an ex-
acerbation of obesity, fluid retention, hypertension and
hyperlipidemia [31]. However, randomized clinical trials
have shown that intensive insulin therapy can prevent or
delay the development of DPN compared to conven-
tional insulin therapy [32]. Another possible explanation
for the association of insulin use with the prevalence off patients with or without DPN
DPN absent Correlation coefficient p value
153.4 (±9.5) 0.167 <0.05
58.6 (±11.2) −0.162 <0.01
24.2 (±4.0) −0.150 <0.01
86.2 (±10.3) −0.151 <0.05
93.6 (±8.9) −0.150 <0.05
0.92 (±0.06) −0.033 NS
138 (±21) 0.030 NS
80 (±12) −0.082 NS
217.1 (±43.2) −0.007 NS
142.3 (±44.2) 0.013 NS
45.8 (±9.1) 0.063 NS
138.2 (±67.4) −0.133 <0.05








6.7 (2.0 – 9.8)
< 0.01
Sector of residence – urban
rural
reference
1.8 (1.1 – 2.5)
<0.05
Household monthly income -> LKR 25,000
LKR 12,000 – 25,000
< LKR 12,000
reference
1.5 (1.0 – 2.0)
1.4 (1.0 – 1.8)
<0.05
<0.05
Duration of diabetes 1.2 (1.1 – 1.3) <0.05
Triglycerides 1.6 (1.2 – 2.0) <0.05
Height 1.8 (1.2 – 2.4) <0.05
Current smoking - non-smoker
smoker
reference
5.9 (1.4 – 9.7)
<0.05
Alcohol consumption - no
yes
reference





2.7 (1.3 – 5.4)
<0.01
Nephropathy – absentpresent reference
0.6 (0.1 – 2.5)
NS
Hypertension - absentpresent reference
0.8 (0.4 – 1.6)
NS
Obesity - BMI <27.5BMI>=27.5 Reference
1.0 (0.5 – 1.9)
NS
Foot ulcers – absentpresent Reference
10.4 (1.8 – 16.7)
<0.01
Physical activity - inactiveactive Reference
0.9 (0.4 – 2.3)
NS
Drug treatment - metformin
sulphonylurea
Reference
1.8 (1.1 – 2.5)
<0.05
Insulin – not treated with insulin
treated with insulin
Reference
4.3 (1.3 – 6.9)
<0.05
LKR - Sri Lankan Rupees.
Table 5 Prevalence of DPN in regional and other
developed countries
Country Prevalence of DPN (%)
All Male Female
Sri Lanka 24.0% 20.0% 26.4%
Bangladesh [10] 19.7% 20.9% 18.7%
India [25] 29.0% 27.9% 30.8%
Pakistan [26] 39.6%
UK [27] 28.5% 28.5% 28.5%
China [28] 32.0%
Iran [29] 51.7% 49.9% 51.7%
North-Africa [30] 41.0% 38.5% 43.9%
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beta cell failure in this group of patients and may reflect
a later stage in the natural history of diabetes or a
greater severity. Another interesting observation is the
trend towards DPN protection observed in the patients
treated with metformin as opposed to sulphonylureas. It
is known that metformin has multiple effects with direct
vascular implications, such as improvement in lipid pro-
file, prevention of oxidative stress-induced endothelial
cell death and direct neuro-protective effects via inhib-
ition of oxidative stress-related apoptotic cell death in
primary neurons [33]. On the other recent animal stud-
ies have shown that blockage of K+ channels in neurons
by sulphonylureas may selectively potentiate neurotox-
icity [34].
The association of elevated fasting triglycerides with
DPN supports the emerging idea that hyper-triglyceri-
daemia contributes to the development and the pro-
gression of diabetic neuropathy [35]. Elevated serumtriglycerides are commonly associated with insulin re-
sistance and represent a valuable clinical marker of the
metabolic syndrome and the resultant atherogenic po-
tential could contribute towards the progression of
DPN [36]. In addition, Schwann cell lipid metabolism
has also been found to be abnormal in DPN, and
hence elevated triglycerides may represent a blood
marker of the pathological changes in the myelin
structure of nerve [37]. Thus, correction of elevated
triglycerides with dietary control or drug treatment
may have an ameliorative effect on the development
and the progression of DPN. The significant associ-
ation observed between DPN and smoking may at
least in part be secondary to the vascular effects smok-
ing, as there has been increasing evidence of the im-
portance of microvascular factors in the pathogenesis
of DPN [38].
The presence of DPN was associated with rural sector
of residence and lower household income. A possible ex-
planation for the phenomenon could be that poor people
are less likely to use health services, which might result
in delayed diagnosis and poor control of DM [39]. Previ-
ous studies have reported that metabolic control of DM
was worse in patients with a lower socio-economic sta-
tus [40]. In addition, the increased risk in rural sector
residents could be due to lack of access to the better
health care facilities available to residents in urban areas.
The association of increased height with DPN indicates
that increased stature has a generalized adverse effect on
peripheral nerve function. The increased nerve length in
taller people is associated with greater axon surface area.
Therefore, persons with longer nerves (and thus a larger
total axon surface area) may be at greater risk for neuro-
logic impairment when exposed to otherwise equivalent
hazards. Greater leg length might also be associated with
a prolonged time requirement for the complete regener-
ation of any injured nerve [41]. Finally, in the present
study female gender was associated with an increased
risk of developing DPN. The finding is not in agreement,
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Diabetes Control and Complications Trial, where neur-
opathy at baseline were significantly more likely in males
[42]. Further studies are required to determine if there
are true gender related differences in the risk of develop-
ing DPN.
Several variables such as obesity, presence of hyper-
tension, high serum cholesterol and alcohol consump-
tion identified as predictors of DPN in other
populations did not emerge as independent predictors
in the present study. According to our results subjects
with DPN had a significantly lower body weight, BMI
and waist circumference. In addition presence of obesity
was not a significant risk factor for DPN in logistic re-
gression analysis. Several studies from Asian countries
have also reported similar results or no association be-
tween obesity and presence of DPN [10]. Hence, further
studies are required to define the role of body weight in
DPN in the Asian population. We also found little evi-
dence for an important role of blood pressure, even
though in other studies hypertension emerged as a
strong risk factor [43]. The reasons for these discrepant
findings are not clear. Our study has several limitations.
The “duration of diabetes” as measured in this study
might not reflect the true duration of the disease but
the time since diagnosis and actual diabetes onset might
precede diagnosis by several years. We were also unable
to assess the impact of glycaemic control on presence of
DPN, as data on HbA1c values were not available for
the majority of the population.
Conclusions
The present study defines the impact of previously
known risk factors for the development of diabetic per-
ipheral neuropathy in the South-Asian population, while
in addition identifies several new potential risk factors of
importance in this ethnically different large sub popula-
tion with diabetes. The examination of these patients in
the future may lead to identification of factors which
have led to the development of neuropathy or the pro-
gress of established neuropathy, which will enable risk
reduction strategies to be developed.
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